Zevra Therapeutics, Inc. (ZVRA): Depreciation & Amortization
$4.05M
Year ended 2025-12-31
$1.49M
Trailing 12 months to 2026-06-30
+62.5%
3-year compound annual growth
+71.5%
5-year compound annual growth
+47.4%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.05M | -36.5% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $6.39M | +535.1% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $1.01M | +6.6% | 2025-03-12, From 2023-01-01 |
| 2022-12-31 | $944.0K | +267.3% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $257.0K | -5.9% | 2023-03-07, From 2021-01-01 |
| 2020-12-31 | $273.0K | -10.2% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $304.0K | -6.2% | 2021-03-12, From 2019-01-01 |
| 2018-12-31 | $324.0K | -3.6% | 2020-02-28, From 2018-01-01 |
| 2017-12-31 | $336.0K | +92.0% | 2019-03-01, From 2017-01-01 |
| 2016-12-31 | $175.0K | +108.3% | 2018-03-30, From 2016-01-01 |
| 2015-12-31 | $84.0K | +12.0% | 2018-03-30, From 2015-01-01 |
| 2014-12-31 | $75.0K | +10.3% | 2017-03-10, From 2014-01-01 |
| 2013-12-31 | $68.0K | n/a | 2016-03-16, From 2013-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $4.05M | -36.5% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $307.0K | -6.7% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $2.48M | +60.2% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $562.6K | +4.5% |
| Xencor Inc (XNCR) | 2025-12-31 | $10.51M | -13.2% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $10.12M | +6.2% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $8.03M | +0.9% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $9.26M | -26.0% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $1.37M | n/m |
Compare ZVRA, URGN, GYRE, SIGA side by side · Screen every company in Pharmaceutical Preparations ↗